{"nctId":"NCT01397422","briefTitle":"Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)","startDateStruct":{"date":"2011-07"},"conditions":["Dyskinesia","Levodopa Induced Dyskinesia","Parkinson's Disease"],"count":83,"armGroups":[{"label":"Treatment A","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: ADS-5102 (extended release amantadine HCl)"]},{"label":"Treatment B","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: ADS-5102 (extended release amantadine HCl)"]},{"label":"Treatment C","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: ADS-5102 (extended release amantadine HCl)"]},{"label":"Treatment D","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: ADS-5102 (extended release amantadine HCl)"]}],"interventions":[{"name":"ADS-5102 (extended release amantadine HCl)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Signed a current IRB/IEC-approved informed consent form\n* Parkinson's disease, per UK Parkinson's Disease Society (UKPDS) Brain Bank Clinical Diagnostic Criteria\n* On a stable regimen of antiparkinson's medications , including any levodopa preparation administered not less than three times daily, and willing to continue the same doses and regimens during study participation\n* Experiencing troublesome dyskinesia following levodopa dosing (peak dose dyskinesia)\n* Able to understand and complete a standardized PD home diary, following training\n\nExclusion Criteria:\n\n* History of neurosurgical intervention related to Parkinson's disease (e.g. deep brain stimulation)\n* History of seizures or stroke/TIA within 2 years of screening\n* History of cancer within 5 years of screening, except adequately treated non-melanomatous skin cancers, localized bladder cancer, non-metastatic prostate cancer or in situ cervical cancer\n* Estimated GFR \\< 50 mL/min/1.73m2\n* Presence of cognitive impairment, as evidenced by a Mini-Mental Status Examination (MMSE) score of less than 24 during screening\n* If female, is pregnant or lactating, or has a positive pregnancy test result pre-dose\n* If a sexually active female, is not surgically sterile or at least 2 years post-menopausal, or does not agree to utilize an effective method of contraception from screening through at least 4 weeks after the completion of study treatment\n* Treatment with an investigational drug or device within 30 days prior to screening\n* Treatment with an investigational biologic within 6 months prior to screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"30 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in the Unified Dyskinesia Rating Scale (UDysRS) Total Score From Baseline to Week 8","description":"The UDysRS is a dyskinesia rating scale from 0-104, and it evaluates involuntary movements associated with PD. A higher score indicates more severe PD. The last observation carried forward (LOCF) method was used for analysis. Participants were summarized according to the actual treatment received.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.7","spread":"2.68"},{"groupId":"OG001","value":"-12.3","spread":"2.88"},{"groupId":"OG002","value":"-17.9","spread":"2.82"},{"groupId":"OG003","value":"-16.7","spread":"2.88"}]}]}]},{"type":"SECONDARY","title":"Change in the Fatigue Severity Score (FSS) From Baseline to Week 8","description":"The FSS is a 9-item self-reported scale, rating subject experience of fatigue during the previous 7 days. The total score, on a scale from 1-7, is represented by the mean of all answered items. The higher the score, the greater the fatigue severity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.25","spread":"0.267"},{"groupId":"OG001","value":"-0.06","spread":"0.289"},{"groupId":"OG002","value":"-0.55","spread":"0.280"},{"groupId":"OG003","value":"0.00","spread":"0.287"}]}]}]},{"type":"SECONDARY","title":"Change in Total Objective Score (III, IV) of the UDysRS From Baseline to Week 8","description":"UDysRS Part III measures objective impairment (dyskinesia severity, anatomic distribution, and type, based on 4 observed activities); and Part IV measures objective disability based on Part III activities. The scores for the 2 Parts combined range from 0-44; a higher score represents more severe dyskinesia.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":"1.19"},{"groupId":"OG001","value":"-4.4","spread":"1.26"},{"groupId":"OG002","value":"-7.1","spread":"1.24"},{"groupId":"OG003","value":"-8.3","spread":"1.26"}]}]}]},{"type":"SECONDARY","title":"Change in ON Time Without Troublesome Dyskinesia (ON Without Dyskinesia Plus ON With Non-troublesome Dyskinesia) From Baseline to Week 8; Based on a Standardized PD Home Diary","description":"A PD home diary was used to score 5 different conditions in 30-minute time intervals: ASLEEP, OFF, ON (ie, had adequate control of PD symptoms) without dyskinesia, ON with non-troublesome dyskinesia, and ON with troublesome dyskinesia. The results were based on 2 consecutive 24-hour diaries taken prior to the day of randomization and prior to the Week 8 visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"0.76"},{"groupId":"OG001","value":"4.1","spread":"0.82"},{"groupId":"OG002","value":"3.8","spread":"0.79"},{"groupId":"OG003","value":"3.6","spread":"0.83"}]}]}]},{"type":"SECONDARY","title":"Change in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Combined Scores (Parts I, II, III) From Baseline to Week 8","description":"The MDS-UPDRS Parts I, II, and III examined non-motor experiences of daily living, motor experiences of daily living, and motor examination, respectively. Each part had sub scales ranging from normal = 0 to severe = 4.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"3.08"},{"groupId":"OG001","value":"0.0","spread":"3.22"},{"groupId":"OG002","value":"-3.4","spread":"3.31"},{"groupId":"OG003","value":"0.5","spread":"3.23"}]}]}]},{"type":"SECONDARY","title":"Clinician's Global Impression of Change (CGI-C) in Overall PD Symptoms From Baseline to Week 8","description":"The CGI-C consisted of a single question that assessed the investigator's global impression of the subject's change from Baseline in overall PD symptoms, including but not limited to LID. The CGI-C required that the investigator rate the extent to which the subject's PD had improved or worsened (from marked worsening to marked improvement).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"7","spread":null},{"groupId":"OG003","value":"4","spread":null}]},{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"8","spread":null},{"groupId":"OG003","value":"6","spread":null}]},{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"5","spread":null}]},{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"2","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"2","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":22},"commonTop":["Constipation","Dizziness","Fall","Dry mouth","Hallucination, visual"]}}}